英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
labore查看　labore　在百度字典中的解释百度英翻中〔查看〕
labore查看　labore　在Google字典中的解释Google英翻中〔查看〕
labore查看　labore　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Understanding Regulatory Expectations for Post-Approval Changes in ANDAs
    Approval Changes in ANDAs Olugbenga “Gbenga” Okubadejo, PharmD Division Director, DRBPM III (Post Marketing Activities) Office of Program and Regulatory Operations Office of Pharmaceutical
  • FDA postmarketing safety labeling changes: What have we learned since . . .
    changes or associated FDA safety-related communications For each study, we extracted information on research design and findings for key clinical outcomes and behaviors We also conducted a ROBINS-I review to identify potential for bias in the research design of each study Results: We found that the estimated impacts of FDA labeling changes
  • Regulatory change management enhancement and transformation - KPMG
    of regulatory information that updates automaticallyacross the enterprise as changes occur 01 Scoping inventory — Regional regulatory laws and rules data is an ongoing sourcing opportunity for firms, where many address regulatory data acquisition manually, in-house — Significant advancements deserve a new look at
  • FDA and EMA Finalize Guidances to Help in Postapproval Change . . .
    regulatory expectations for postapproval CMC changes In both cases, the final versions were impacted by a plethora of comments that came in on the drafts – reflective of the level of industry concern with the global filing burdens when making CMC changes The two guidances and the changes incorporated based on the comments, in turn, bear witness
  • Explaining the Recent Draft Guidelines Issued by the FDA Concerning . . .
    medicine and biologics) is an ongoing priority of Regulatory Agencies worldwide This year the US Food and Drug Administration (FDA) drafted guidelines on best practice in aiding the prevention of shortages which may be caused by disruptions in the supply chain either by raw materials supply, manufacturing difficulties, or natural disasters such as
  • DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Docket No FDA-_____ Preliminary Regulatory Impact Analysis We have examined the impacts of the proposed rule under Executive Order 12866, Executive Order 13563, Executive Order 13771, the Regulatory Flexibility Act (5 U S C 601- system management of their medical devices – current Part 820 and ISO 13485 Although the
  • IMPACT OF THE NEW ADMINISTRATION FDA LIFE SCIENCES COMPANIES
    •FDA revoking the use of Red No 3 in food and ingested drugs •FDA proposed rule regarding Front-of-Package Nutrition Labeling •FDA final rule on the “Healthy” nutrient content claim which is not effective until February 25, 2025 •FDA final rule on traceability (FSMA 204) which is not effective until January 2026
  • TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT . . .
    Regulatory mechanisms that allow the timely and efficient introduction of CMC changes are important drug quality, safety,for and availability There is a range of potential CMC changes for which communication between a company and the regulatory authority is required CMC changes vary from low to high potential risk
  • Changes to an Approved NDA or ANDA
    to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U S C 3501-3520) The collection(s) of information in this guidance were approved under
  • Introduction to Division of Risk Management (DRM) - fda. report
    Updates to 2007 REMS Authorities • Appropriations Act of 2020 www fda gov • July 2012 - FDA Safety and Innovation Act (FDASIA) • December 2016 - 1 st Century Cures Act • October 2018 - Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act
  • WHITE PAPER DESIGN CHANGES: THE MANAGEMENT OF CHANGES BEFORE AND AFTER . . .
    Change to an Existing Device” guidelines, most recent publication of 2017 In general, the project changes that may require evaluation (to decide whether to communicate them to FDA though a 510(k) notification) can result from different sources: adverse events, risk management process, changes in the production process or the technology
  • Benefit-Risk Assessment Throughout the Drug Lifecycle: FDA Discussion . . .
    FDA’s benefit-risk assessment is the process by which FDA integrates the above factors to inform regulatory decisions FDA’s vehicle for conducting these assessments is the Benefit-Risk Framework for Human Drug Review 11 The Benefit-Risk Framework (Figure 1) provides a structured, qualitative
  • The New Drug Approval Process: NDA Submission and Review
    Drug Master Files (DMFs) • Submission to FDA of information concerning facilities, processes, or ingredients for a drug • Method for supplying information in a confidential manner • May be referenced by “DMF holder” or others (with permission) in an application (e g , IND, NDA, or ANDA) • DMF Types: – Type II: Drug substance – Type III: Packaging materials
  • Postapproval Changes to Drug Substances Guidance for Industry
    65 Under 21 CFR 314 70, 314 97, and 514 8, application holders must notify FDA about changes to 66 conditions established in approved applications beyond the variations already provided for in 67
  • Guidance for Industry Q10 Pharmaceutical Quality System
    Quality risk management can be useful for identifying and prioritizing areas for continual improvement E Enablers: Knowledge Management and Quality Risk Management (1 6) Use of knowledge





中文字典-英文字典  2005-2009